Quarterly ResultJul 30, 2026, 04:13 PM
CareDx Reports Q2 Net Income $110.6M, Driven by Lab Products Sale
AI Summary
CareDx reported a substantial turnaround in its financial performance for the second quarter of 2026, achieving a net income of $110.6 million, or $2.07 diluted EPS, compared to a net loss in the prior year. This significant improvement was primarily driven by a $113.0 million gain from the sale of its lab products business. The company also saw a 52.2% increase in total revenue to $131.9 million and a substantial boost in cash and cash equivalents.
Key Highlights
- Net income for Q2 2026 was $110.6 million, a significant increase from a net loss of $8.6 million in Q2 2025.
- Diluted EPS for Q2 2026 was $2.07, up from $(0.16) in Q2 2025.
- Total revenue for Q2 2026 increased 52.2% to $131.9 million from $86.7 million in Q2 2025.
- Recognized a gain of $113.0 million on the sale of the lab products business.
- Cash and cash equivalents increased to $373.6 million as of June 30, 2026, from $65.4 million at December 31, 2025.
- Net cash provided by operating activities for H1 2026 was $34.9 million, compared to net cash used of $16.7 million in H1 2025.
Price Impact
More from CDNA